France Biotech and AFCROS express fears amid French clinical trial deadlock

2 April 2015

France Biotech and AFCROS, the French industry body for clinical research, have spoken out on the need to preserve and safeguard the excellence of the research sector and its jobs.

AFCROS has issued a statement which it says is "ringing the alarm bell" on the extent to which France has lost its position as an attractive proposition for clinical research. The trade group has been drawing the attention of stakeholders, especially public authorities, to the detrimental effect of the current deadlock in analyzing clinical trial data if it is not swiftly resolved.

Six regional commmittees stop accepting dossiers

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >